The European Medicines Agency (EMA) said that Indian authorities have withdrawn certification to the Toansa plant, while an international inspection of the Dewas plant has been planned for June 2014.
Exports from Ranbaxy plants at Toansa and Dewas to Europe will remain suspended as probes are continuing even as Indian authorities have withdrawn the certification of manufacturing standards from one of the units, European health regulator EMA said today.
The European Medicines Agency (EMA) said that Indian authorities have withdrawn certification to the Toansa plant, while an international inspection of the Dewas plant has been planned for June 2014. "The EMA and national medicines authorities in the EU are progressing with their assessment of reports of non-compliance with Good Manufacturing Practice (GMP) at two Ranbaxy Laboratories' sites in India," a EMA spokesperson told PTI.
Also Read: Can Sun Pharma defy law of averages on M&A deal trend?
Exports from Toansa and Dewas sites to the EU will remain suspended, the spokesperson said without specifying a timeline for completion of investigations. On the Toansa plant, the official said: "On March 26, 2014, Indian authorities withdrew the site's 'Written Confirmation', effectively making the suspension of the exports official for the time being."
The Written Confirmation is a document that accompanies all APIs (active pharmaceutical ingredients) exported to the EU to certify that relevant manufacturing standards have been. "In the meantime, the EMA and national medicines authorities in the EU are continuing to work together to ensure that failings previously identified at the site are fully resolved before there is a resumption of exports from the site to the manufactures in the EU," it said.
Ranbaxy had voluntarily suspended exports from the sites to the EU in January 2014. The EMA said a second unannounced international probe of the Toansa site was conducted after the USFDA banned products from the plant in January. The preliminary findings of the inspection carried out jointly by authorities from Germany, the UK, Ireland, Switzerland and Australia did not highlight any additional issues beyond those already identified.
The Toansa site had been supplying APIs for four centrally authorised medicines - Enyglid (repaglinide), Repaglinide Krka (repaglinide), Repaglinide Teva (repaglinide), and Nevirapine Teva (nevirapine) - and several non-centrally authorised medicines in Europe. When contacted a Ranbaxy spokesperson declined to comment.
Ranbaxy Labs stock price
On April 09, 2014, Ranbaxy Laboratories closed at Rs 467.00, up Rs 21.80, or 4.90 percent. The 52-week high of the share was Rs 505.00 and the 52-week low was Rs 253.95.
The latest book value of the company is Rs 3.41 per share. At current value, the price-to-book value of the company was 136.95.
Anda sedang membaca artikel tentang
Exports to EU from Ranbaxy's two plants to remain suspended
Dengan url
http://kebugaranhidup.blogspot.com/2014/04/exports-to-eu-from-ranbaxys-two-plants.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Exports to EU from Ranbaxy's two plants to remain suspended
namun jangan lupa untuk meletakkan link
Exports to EU from Ranbaxy's two plants to remain suspended
sebagai sumbernya
0 komentar:
Posting Komentar